Hubei Jumpcan Pharmaceutical (600566) H2 2024 earnings summary

Executive summary

• Revenue for 2024 was RMB 8.02 billion, down 16.96% year-over-year; net profit attributable to shareholders was RMB 2.53 billion, down 10.32%.

• Cash flow from operations dropped 37.17% year-over-year due to lower sales collections.

• R&D investment reached RMB 452.77 million, accounting for 5.65% of revenue.

• The company maintained a leading position in pediatric and respiratory drug segments.

Financial highlights

• Operating income: RMB 8.02 billion, down 16.96% year-over-year.

• Net profit attributable to shareholders: RMB 2.53 billion, down 10.32% year-over-year.

• Operating cash flow: RMB 2.18 billion, down 37.17% year-over-year.

• Basic EPS: RMB 2.76, down 10.39% year-over-year.

• Gross margin: 79.34%, down 2.29 percentage points year-over-year.

Outlook and guidance

• Focus on dual growth drivers: internal innovation and external expansion.

• Continued investment in R&D, new product launches, and digital transformation.

• Emphasis on pediatric, respiratory, and digestive therapeutic areas.